NAT-POMALIDOMIDE
As listed in the register: NAT-POMALIDOMIDE
2 mg · capsule
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Pomalidomide
- Made by
- Natco Pharma (Canada) Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Pomalidomide). It describes the substance, not this exact product.
Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties.
Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex.
Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4.
Following a single oral administration of [ 14 C]-pomalidomide to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and feces, respectively, with approximately 2% and 8% of the radiolabeled dose eliminated unchanged as pomalidomide in urine and feces.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-01
Safety of the active substance
From the US prescribing label for the same active substance (Pomalidomide). It describes the substance, not this exact product.
WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM Embryo-Fetal Toxicity Pomalidomide capsules are contraindicated in pregnancy.
- Pregnancy (4.1) Hypersensitivity (4.2) 4.1 Pregnancy Pomalidomide capsules are contraindicated in females who are pregnant.
- Pomalidomide capsules can cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
- Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis.
- If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus. 4.2 Hypersensitivity Pomalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, anaphylaxis) to pomalidomide or any of the excipients [see Warnings and Precautions (5.7), Description (11)].
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States11 matching products
European UnionNo exact match for this strength and form
Spain12 matching products
France7 matching products
Netherlands23 matching products
- Pomalidomide Synthon 2 mg 2 mg · capsule, hard2 makers
- Imnovid 2 mg 2 mg · capsule, hard
- Polidma 2 mg 2 mg · capsule, hard
- Pomalidomide Accord 2 mg harde capsules 2 mg · capsule, hard
- Pomalidomide Adalvo 2 mg 2 mg · capsule, hard
- Pomalidomide CF 2 mg 2 mg · capsule, hard
- Pomalidomide Devatis 2 mg 2 mg · capsule, hard
- Pomalidomide Eugia 2 mg 2 mg · capsule, hard
SwitzerlandNo exact match for this strength and form
Details
| Made by | Natco Pharma (Canada) Inc |
|---|---|
| Active substance | Pomalidomide |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 2 mg |
| Form | capsule |
| Classification | L04AX06 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02506408 |
| DPD drug code | 99577 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.